1. Introduction {#sec1}
===============

The number of patients with dementia have been increasing exponentially with the aging of society in advanced countries and Asian countries. About 24,300,000 people are expected to have dementia worldwide, and there are already more than 2,000,000 people with dementia in Japan. A half of dementia were caused by Alzheimer disease (AD). The development of AD research has clarified that the pathogenesis of AD is initiated by A*β* amyloidosis with secondary tauopathy and provided a strategy for investigating drugs that may improve or cure AD. Mild cognitive impairment (MCI) as a prodromal stage of AD and the pathogenesis of Dementia with Lewy bodies (DLB) and Frontotemporal lobar degeneration (FTLD) as a non-AD type dementia have also been elucidated. Currently, a consortium study by the Alzheimer Disease Neuroimaging initiative (ADNI) is being performed to establish global clinical evidence regarding a neuropsychiatric test battery, CSF biomarkers, neuroimaging including MRI, FDG-PET, and amyloid PET to predict progression from MCI to AD and to promote studies of basic therapy for AD \[[@B1]\]. Several new biomarkers such as A*β* oligomer, *α*-synuclein, and TDP-43 are now under investigation for further determination of their usefulness to detect AD and other non-AD type dementia.

2. Cerebrospinal Fluid A***β***40, A***β***42, Tau, and Phosphorylated Tau {#sec2}
==========================================================================

These biomarkers have been used for a clinical diagnosis of AD, discrimination from the Vascular dementia (VaD) and non-AD type dementia, exclusion of treatable dementia and MCI, prediction of AD onset and evaluation of the clinical trials of an anti-A*β* antibody, A*β* vaccine therapy, and secretase inhibitors \[[@B2]--[@B4]\]. A*β* amounts in cerebrospinal fluid (CSF) are controlled by orexin, suggesting the presence of a daily change in the CSF A*β* amounts, that is, A*β* levels are high while awake and low while a sleep. Collection of CSF by lumbar puncture early in morning in a fasting state is recommended \[[@B5]\]. A*β* is produced mainly in the nerve cells of the brain, and it is secreted about 12 hours later into the CSF, then excreted through the blood-brain barrier 24 hours later into blood (A*β* clearance), and finally degraded in the reticuloendothelial system. A*β* levels are regulated in strict equilibrium among the brain, CSF, and blood \[[@B6], [@B7]\]. In AD brains, A*β*42 forms insoluble amyloids and accumulates as insoluble amyloid fibrils in the brain. The reason A*β*42 levels are decreased in the CSF of AD patients is considered to be caused by deterioration of physiologic A*β* clearance into the CSF in AD brains \[[@B2], [@B3]\].

CSF total tau levels increase slightly with aging. However, CSF tau levels show a 3-fold greater increase in AD patients than in normal controls \[[@B8]\]. It is thought that the rise in CSF total tau is related to degeneration of axons and neurons and to severe destructive disease of the nervous system. Several diseases show slightly increased tau levels such as VaD, multiple sclerosis, AIDS dementia, head injury, and tauopathy. However, CSF tau levels show significant increases in Creutzfeldt-Jakob disease (CJD) and meningoencephalitis \[[@B8]\].

3. Methods for Measurement of CSF and Plasma Biomarkers {#sec3}
=======================================================

CSF and plasma A*β*40 and A*β*42 amounts can be measured with an Amyloid ELISA Kit (Wako), which is commercially available and used worldwide. The ELISA kit was developed in Japan by Suzuki et al. and shows extremely highly sensitivity and reproducibility \[[@B9]\]. INNOTEST *β*-AMYLOID1-42 (Innogenetics), for A*β*42 is used widely in Europe and America. Several assay kits for total tau and phosphorylated tau are also used for the measurement of CSF tau. Currently, total tau is measured using INNOTEST hTau Ag (Innogenetics). There are 3 ELISA systems for measurement of phosphorylated tau that recognize the special phosphorylation sites at Ser199 (Mitsubishi Chemical Corp.), Thr181 (Innogenetics) and Thr231 (Applied NeuroSolutions Inc.), and phosphorylated tau levels are increased in CSF of AD on assays using these kits. Of these 3 kits, INNOTEST PHOSPHO-TAU (181) (Innogenetics) is commercially available and used widely. Recently, INNO-BIA AlzBio3 by Innogenetics has been able to measure A*β*1-42, total tau, and P-tau181P simultaneously in 75 *μ*L of CSF, which is a very small amount of CSF.

4. Clinical Evidence, Sensitivity, and Specificity {#sec4}
==================================================

The first large-scale collaborative multicenter study of CSF A*β*40, A*β*42, and total tau as biomarkers of AD was reported by a Japanese study group in 1998 \[[@B4]\]. A total of 236 subjects were followed and evaluated using a combination index (AD index: CSF A*β*40/A*β*42 × total tau), which showed a diagnostic sensitivity of 71% and specificity of 83% in AD. The diagnostic sensitivity rose to 91% on continuous follow-up study. This study continued until 2004. Finally, diagnostic sensitivity was 80% and specificity was 84% in a total of 507 subjects (157 AD patients, 88 control subjects, 108 non-Alzheimer-type dementia patients, 154 nondementia disease patients) \[[@B10]\]. An European and American large scale multicenter study reported that a combination assay of A*β*42 and tau in CSF samples from 100 controls, 84 non-dementia neurological diseases, 150 AD, and 79 non-AD type dementia showed a diagnostic sensitivity of 85% and specificity of 86% \[[@B11]\]. A large-scale multicenter Japanese study of CSF total tau alone in 1,031 subjects (366 AD, 168 non-AD dementia, 316 non-dementia neurological diseases, and 181 normal controls) reported a sensitivity of 59% and specificity of 90% for diagnosis of AD \[[@B8]\]. After these studies, many combination studies reported decreased A*β*42 and increased tau in CSF from AD patients. Practical guidelines for dementia proposed by the American Academy of Neurology in 2001, which were based on a systematic review of all reports between 1994 and 1999, showed that there were 4 Class II or Class III studies on CSF A*β*42 reporting a diagnostic sensitivity of 78\~92% and specificity of 81\~83%. Regarding CSF tau levels in AD, there were also 4 Class II or Class III studies reporting a diagnostic sensitivity of 80\~97% and specificity of 86\~95%. Three Class II or III reports were selected for a systematic review of combination study of A*β*42 and total tau in CSF. This review also evaluated the sensitivity as 85% and specificity as 87% \[[@B12]\]. A community-based prospective study showed that the diagnostic sensitivity for AD was 94% (probable AD), 88% in possible AD, and 75% in MCI. The specificity was 100% (mental diseases) and 89% in non-dementia subjects. The specificity was low in DLB (67%) and VaD (48%). Sensitivity was increased in subjects having the ApoE *ε*4 genotype \[[@B13]\]. A comparative study based on pathological findings reported that the diagnostic sensitivity was 85% and specificity was 84% \[[@B14]\]. Meta-analysis of 17 reports on CSF A*β*42 and 34 reports on CSF total tau (3,133 AD subjects in total with comparison to 1,481 normal controls subjects) was performed in 2003, and showed a final diagnostic sensitivity of 92% and specificity of 89% \[[@B15]\]. Global standardization of the assay system using normal subjects has also been carried out.

In the examination of CSF phosphorylated tau, the first study of p-tau199 was reported as a large-scale multicenter collaborative study by a Japanese group. A total of 570 subjects were analyzed (236 AD, 239 non-AD and non-dementia neurological diseases, and 95 normal controls) and showed a diagnostic sensitivity of 85% and specificity of 85% in a comparison between AD and non-AD disease controls \[[@B16]\]. Assay systems using different epitopes of phosphorylated tau (p-tau231, p-tau181, and p-tau199) have been internationally standardized. When the sensitivity was fixed above 85%, the respective specificities were 83% for p-tau231, 79% for p-tau199, and 60--71% for p-tau181 \[[@B17]\]. Currently, the assay system for p-tau181 tau is widely used to measure phosphorylated tau in CSF. Systematic review of CSF biomarkers for AD in 2001 analyzed 41 studies (2,500 AD, 1,400 controls) of CSF total tau, 15 studies (600 AD, 450 controls) of A*β*42 and 11 studies (800 AD, 370 controls) of p-tau, 5 studies (Mild AD) for diagnosis of early AD, and 9 studies of MCI and showed that the respective specificities and sensitivities were 90% and 81% for CSF total tau, 90% and 86% for CSF A42, 92% and 80% for CSF phosphorylated tau, and 83\~100% and 85\~95% in the combination assay with CSF A*β*42 and total tau \[[@B18]\]. A summary of major large-scale multicenter studies of CSF biomarkers for the diagnosis of AD is shown in [Table 1](#tab1){ref-type="table"}.

5. CSF Biomarkers for Prediction of the Onset of AD from MCI {#sec5}
============================================================

During these past several years, studies of CSF biomarkers have investigated the prediction of progression from MCI to AD ([Table 2](#tab2){ref-type="table"}). A study following 52 MCI subjects for 8.4 months found that 29 MCI subjects developed AD and the specificity of CSF A*β*42 assay was 90% \[[@B19]\]. Follow-up study of 273 subjects (55 MCI, 100 AD, 14 DLB, 11 FTD) for 2 years showed that 38% (20/55) of MCI patients already showed alteration of at least 2 CSF biomarkers including A*β*42, total tau, and p-tau181 at the time of the study initiation. Eleven MCI subjects developed dementia 1 year later, while the remaining 33 subjects stable. Eleven showed a further progression of cognitive impairment, still not fulfilling the diagnostic criteria for dementia. Ten of 11 MCI patients who progressed to AD showed alteration of at least 2 CSF biomarkers, and all 11 converters showed high p181tau levels in CSF. Conversely, 29 (88%) of the 33 stable MCI subjects did not show any alteration of CSF biomarkers \[[@B20]\]. The longest prospective study (4--6 years) followed 137 MCI and 39 normal subjects. Of these 57 subjects (42%) developed AD and 21 subjects (15%) developed dementia due to other causes during followup. Fifty-six subjects (41%) did not show any change during an average followup of 5.2 years. Using CSF A*β*42 and total tau assay, onset of AD was predicted with a sensitivity of 95% and specificity of 83%. The hazard ratio was 17.7. The addition of p181tau assay further improved sensitivity and specificity to 95% and 97%, respectively \[[@B21]\]. In comparison studies between CSF biomarkers and amyloid imaging by PIB-PET, CSF A*β*42 levels were decreased and total and p181 tau levels were increased in very mild AD. CSF A*β*42 levels completely related to brain amyloid deposits detected by PIB-PET in patients with or without dementia \[[@B22]\]. The CSF total tau/A*β*42 ratio and the p181 tau/A*β*42 ratio predicted the exacerbation of CDR score \[[@B9]\].

The usefulness of CSF biomarkers for predicting the progression form MCI to AD was strictly validated by the international consortium study, ADNI performed between 2004 and 2009. In US-ADNI, 819 healthy subjects (55\~90 y; 229 normal, 398 MCI, 192 mild AD) were selected based on less than 4 points on Hatchiski Ischemic score, more than 6 points on GDS score, and a history of more than 6 years of education. MMSE scores ranged from 24 to 30 points in normal controls and MCI, 20--26 points in AD patients. CDR sore was 0 in normal controls, 0.5 in MCI, and 0.5\~1 in AD. On logical memory test II of WMS-R, the score was evaluated as normal (≧9: normal subjects with more than 16 years of education, ≧5: normal subjects with 8\~15 years of education, ≧3: normal subjects with 0\~7 years of education), and as MCI or AD (≦8: subjects with more than 16 years of education, ≦4: subjects with 8\~15 years of education, ≦2: subjects with 0\~7 years of education). The result one year later showed that the mean AD conversion/year was 16.5% (1.4% in those converting from normal to MCI, 16.5% in those converting from MCI to AD, 8 cases reverted from MCI to normal and 2 cases reverted from AD to MCI). About 50% of MCI patients take anticholinesterase or memantine (ChEI: 44% in MCI, 85% in AD; memantine: 11% in MCI, 47% in AD: Combination use of ChEI and memantine: 9% in MCI, 41% in AD). Average deteriorations of ADAS-cog score were 1.1 points/year in MCI and 4.3 points/year in AD. Among all CSF biomarkers, A*β*42 at the initial evaluation was the most reliable marker predicting conversion from MCI to AD and the progression of cognitive impairment. CSF A*β*42 was the most sensitive biomarker for AD in a follow-up study of 100 mild AD, 196 MCI, and 114 normal elderly controls and an associated correlation study using age-matched 52 normal control and 56 AD brains (sensitivity 97%, specificity 77%). The sensitivity and specificity of CSF total tau assay were 70% and 92%, respectively. The sensitivity was 68% and the specificity was 73% for a CSF p-tau181 assay. The sensitivity of the total tau/A*β*42 ratio was 86%, and its specificity was 85%. A*β*42, total tau, and the number of ApoE *ε*4 alleles were the most sensitive biomarkers in the ADNI cohort. Using CSF total tau/A*β*42 ratio, 33 converters (89%) were predicted before onset among 37 subjects who progressed from MCI to AD within one year \[[@B1], [@B23]\]. US-ADNI Penn Biomarker core reported that decreased CSF A*β*42 levels and increased total tau levels were prediction markers for AD with the highest evidence level, and that A*β*42 was the earliest marker among total tau, F^18^FDG-PET, and MRI examination \[[@B24]\]. In addition, there were subgroups of normal subjects who showed rapid deterioration of cognitive function \[[@B25]\]. Hippocampal atrophy detected by MRI was closely related to CSF p-181T au levels in the ApoE 4 carrier group and CSF total tau in the ApoE 4 noncarrier group. Amyloid accumulation in the precuneus detected by the PIB amyloid PET correlated with hippocampal atrophy \[[@B26]\]. CSF p-tau181 amounts were related with cognitive impairment in the normal group, while CSF A*β*42 amounts were correlated with those in the MCI group. These 2 biomarkers more sensitively detected cognitive impairment than ADAS-cog in the normal and MCI groups. In all groups, subjects with alteration of both A*β*42 and p-tau181 levels showed faster deterioration of cognitive function \[[@B27]\].

A prospective study for more than 2 years by 12 European and American centers reported that 271 patients with MCI developed AD and 59 developed non-AD-type dementia among 750 MCI patients. The sensitivity and specificity of using CSF A*β*42, total tau, and p-tau181 were 83% and 72%, respectively \[[@B28]\]. In the DESCRIPA study, 60 SCI subjects (subjective cognitive impairment), 37 non-amnestic MCI (naMCI), 71 amnestic MCI (aMCI), and 89 normal controls were followed for 3 years and examined by CSF biomarkers. In the naMCI group with AD-like alteration of CSF biomarkers (AD profile), 8 (36%) of 22 cases developed AD. In the aMC group, 27 (51%) of 53 cases showing with CSF AD profile developed AD. The CSF AD profile was recognized in 31% of control, 52% of SCI, 68% of naMCI and 79% of aMCI. All converters showed the CSF AD profile and the combination of decreased A*β*42 and increased total tau/p-181tau levels in CSF was a significant risk factor in the aMCI group \[[@B29]\] ([Table 2](#tab2){ref-type="table"}).

6. Plasma A***β***40 and A***β***42 as Risk Factors for AD {#sec6}
==========================================================

Since measurement of plasma A*β*42 and A*β*40 by Matsubara, the decreased ratio of A*β*42 and A*β*40 has been reported as a risk factor for AD onset \[[@B30]\]. The Rotterdam study prospectively studied 1,756 subjects randomly selected from 6,713 participants for an average of 8.6 years and reported that 392 subjects developed dementia. In this study, plasma A*β*40 levels at the start related to the risk of the dementia onset. The age- and sex-adjusted upper quartile with a high plasma A*β*40 showed a hazard ratio of 1.07\~1.46 compared with the other 75% of the group. The upper quartile with a high A*β*42/A*β*40 ratio showed a decreased hazard ratio for onset of dementia of 0.74\~0.47 \[[@B31]\]. The Mayo Clinic prospective study consisted of 563 subjects with a mean age of 78 years old followed for 3.7 years. It was reported that 53 of these subjects developed MCI and AD. Significant increase in the risk of MCI and AD onset was recognized in the lower quartile with a low plasma A*β*42/A*β*40 ratio. Relative risk was 3.1 on comparison between the upper quartile and lower quartile. After a adjusting for age and ApoE genotypes, significant deterioration was recognized in subjects with a low plasma A*β*42/A*β*40 ratio \[[@B32]\]. A prospective study of 1,125 cognitively normal elderly subjects for 4.6 year showed that 104 subjects (9.2%) developed AD. High plasma A*β*42 levels at the start of study increased threefold the risk of AD onset. Once AD developed, however, plasma A*β*42, A*β*42/A*β*40 ratio, and protofibrillar A*β*42 were significantly decreased \[[@B33]\]. The presence of anti-A*β* autoantibody was suggested in human plasma, and the A*β*40/A*β*42 ratio was closely related to progression of cognitive impairment in AD patients \[[@B34]\]. By 2009, two additional large-scale studies were reported \[[@B35], [@B36]\], and the results of the ADNI study are expected in the near future. These findings are summarized in [Table 3](#tab3){ref-type="table"}.

7. Development of Other Biomarkers {#sec7}
==================================

Homocysteine in CSF and plasma were measured in US-ADNI. Significant differences among normal, MCI, and AD groups were observed in plasma, but were not recognized in the CSF. At the same time, there was no significant difference in CSF Isoprostane measured as a marker of oxidation stress \[[@B24]\]. A report of the establishment of ELISA for A*β* oligomer, the main causative molecule of AD, has been attracting attention for measurement of plasma in AD subjects. Plasma A*β* oligomer could be detected in 3 of 10 normal subjects and 19 of 36 AD patients. The level of plasma A*β* oligomer correlated with those of A*β* monomer, and both amounts progressively decreased in familial AD patients \[[@B37]\]. Studies examining CSF *α*-synuclein and TDP-43 levels as biomarkers for DLB, FTLD-TDP, and ALS were reported from Japan. Levels of CSF*α*-synuclein were measured by ELISA in 16 DLB and 21 AD patients, but there were no significant differences; however, a correlation with disease duration was recognized in the DLB group \[[@B38]\]. Measurement of CSF DJ-1 and *α*-synuclein by ELISA in 117 Parkinson\'s disease (PD) patients, 132 normal control and 50 AD patients suggested that age and contamination of blood caused some artifacts, but showed that both markers were decreased in PD compared with those in normal controls and AD. The sensitivity and specificity for CSF DJ-1 were 90% and 70%, and those for CSF *α*-synuclein were 92% and 58%, respectively \[[@B39]\]. Assay of CSF TDP-43 was established by Tokuda, and increased levels of TDP-43 were found in early ALS suggesting an early diagnostic marker of ALS. A further detailed study of the usefulness of CSF TDP-43 in ALS and FTDP-TDP is desired in the near future \[[@B40]\].
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###### 

Eleven major studies of CSF biomarkers for AD published between 1998 and 2009.

  -----------------------------------------------------------------------------------------------------------------------------------------------------
  Study        year   subjects                                biomarker                sensitivity   specificity   other
  ------------ ------ --------------------------------------- ------------------------ ------------- ------------- ------------------------------------
  Kanai        1998   93 AD, 54 cont, 33 nAD, 56 ND           A*β*40, A*β*42, ^†^Tau   71\~91%       83%           Multicenter, prospective

                                                                                                                   

  Hulstaert    1999   150 AD, 100 cont, 79 nAD, 84 ND         A*β*42, ^†^Tau           85%           86%           10 European center

                                                                                                                   

  Knopman      2001   3 Class II, III studies                 A*β*42, ^†^Tau           80\~97%       86\~95%       System review AAN

                                                                                                                   

  Andreasen    2001   163 AD, 23 VaD, 20 MCI, 9 DLB, 8 ND,\   A*β*42, ^†^Tau           75\~94%       89\~100%      1 Y-prospective
                      18 cont                                                                                      

                                                                                                                   

  Itoh         2001   236 AD, 239 nAD/ND, 95 cont,            PTau199                  85%           85%           multicenter

                                                                                                                   

  Shoji        2002   366 AD, 181 cont,\                      ^†^Tau                   59%           90%           multicenter
                      168 nAD, 316 ND                                                                              

                                                                                                                   

  Clark        2003   106 dementia, 73 cont                   A*β*42, ^†^Tau           85%           84%           2\~8 Y follow up autopsy confirmed

                                                                                                                   

  Sunderland   2003   17A*β*42 studies, 34 tau studies\       A*β*42, ^†^Tau           92%           89%           Meta-analysis
                      (3133 AD versus 1481 control)                                                                

                                                                                                                   

  Blennow      2003   41Tau studies\                          A*β*42,\                 86%\          90%\          Systematic review\
                      (2500 AD versus 1400 cont)\             ^†^Tau,\                 90%\          81%\          Early AD, MCI
                      15A*β*42 studies\                       PTau\                    92%\          80%\          
                      (600 AD versus 450 cont)\               A*β*42/tTau              85\~94%\      83\~100%      
                      11p-Tau studies\                                                                             
                      (800 AD versus 370 cont)                                                                     

                                                                                                                   

  Hampel       2004   161 AD/FTD/DLB/VaD, 45 cont             PTau231\                 85%           83%,\         International harmonization
                                                              pTau181\                               79%,\         
                                                              pTau199                                60\~71%       

                                                                                                                   

  GTT3         2004   243 AD, 91 cont, 152 nAD, 157 ND        A*β*40, A*β*42, ^†^Tau   80%           84%           Continuous GTT1
  -----------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Major studies of CSF biomarker to predict progression from MCI to AD published between 2004 and 2010.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study      Year   Case        Follow-up   MCI to AD                               Marker                    Sensitivity                                                         Specificity                          Other
  ---------- ------ ----------- ----------- --------------------------------------- ------------------------- ------------------------------------------------------------------- ------------------------------------ --------------------
  Hampel     2004   52 MCI\     8.4 M       29/52 (56%)                             A*β*42, ^†^Tau            A*β*42 59%\                                                         A*β*42 100%\                         European cohort
                    93 AD\                                                                                    ^†^Tau 83%                                                          ^†^Tau 90%                           
                    10 cont                                                                                                                                                                                            

                                                                                                                                                                                                                       

  Parnetti   2006   55 MCI\     1 Y         11/55 (20%)\                            A*β*42, ^†^Tau, pTau181   2 biomarker abnormality\                                            Normal markers in stable MCI (88%)   Mayo Clinic Cohort
                    100 AD\                 38% of MCI has 2 marker abnormalities                             in AD converters (91%)                                                                                   
                    14 DLB\                                                                                                                                                                                            
                    11 FTD\                                                                                                                                                                                            

                                                                                                                                                                                                                       

  Hansson    2006   137 MCI\    4\~7 Y      57 AD (42%)\                            A*β*42, ^†^Tau, pTau181   A*β*42/^†^Tau 95%\                                                  A*β*42/^†^Tau 83%\                   Prospective study
                    39 cont                 21 nonAD dementia (15%)\                                          A*β*42/^†^Tau/\                                                     A*β*42/^†^Tau/\                      
                                            56 stable MCI (41%)                                               pTau181 95%                                                         pTau181 87%                          

                                                                                                                                                                                                                       

  Show       2009   100 AD\     1 Y         37/191 (19%)                            A*β*42, ^†^Tau, pTau181   Tau/A*β*42 predicted 89% of AD converters\                          US-ADNI                              
                    191 MCI\                                                                                  CSF A*β*42 highly correlated with brain pathology                                                        
                    114 cont                                                                                                                                                                                           

                                                                                                                                                                                                                       

  Mattsson   2009   750 MCI\    \>2 Y       271 AD/750 MCI (36%)\                   A*β*42,\                  83%                                                                 73%                                  12 centers\
                    529 AD\                 59 nonAD\                               ^†^Tau,\                                                                                                                           Europe/US
                    304 cont\               dementia/750 MCI                        pTau181                                                                                                                            

                                                                                                                                                                                                                       

  Visser     2009   60 SCI\     3 Y         8/22 CSF/AD naMCI (36%)\                A*β*42, ^†^Tau, pTau181   CSF/AD was observed in control 31%, SCI 52%, naMCI 68%, aMCI 79%\   DESCRIPA study\                      
                    37 naMCI\               27/53 CSF/AD aMCI (51%)                                           All AD had CSF/AD\                                                  Europe study                         
                    71 aMCI\                                                                                  CSF/AD is a significant risk in aMCI                                                                     
                    89 cont                                                                                                                                                                                            
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SCI: subjective cognitive impairment; naMCI: nonamnesctic MCI; aMCI: amnestic MCI; CSF/AD: CSF AD profile (decreased A*β*42/increased tau).

###### 

Major studies of plasma A*β*40 and A*β*42.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study           Year   Follow              Subject         Marker                                 Results                                                                                                            Journal
  --------------- ------ ------------------- --------------- -------------------------------------- ------------------------------------------------------------------------------------------------------------------ ---------------
  Matsubara       1999   ---                 36 AD\          Lipoprotein free A*β*40, A*β*42        Increased plasma lipoprotein free A*β*42 in AD and Down Syndrome                                                   Ann Neurol
                                             206 cont\                                                                                                                                                                 
                                             6 DS                                                                                                                                                                      

                                                                                                                                                                                                                       

  Van Oijen       2006   8.6 Y\              1,756/6,713     A*β*40, A*β*42\                        396 cases developed dementia during follow up\                                                                     Lancet Neurol
                         Rotterdam\                          A*β*42/A*β*40                          Increased A*β*40 level was a risk for onset of dementia\                                                           
                         study\                                                                     Increased A*β*42/A*β*40 ratio decreased the risk for onset of dementia                                             

                                                                                                                                                                                                                       

  Graff-Radford   2007   3.7 Y Mayo Cohort   563 control     A*β*40, A*β*42 A*β*42/A*β*40           53 cases developed MCI and AD\                                                                                     Arch Neurol
                                                                                                    Significantly increased risk for onset of MCI and AD (3.1) in lower 25% group with decreased A*β*42/A*β*40 ratio   

                                                                                                                                                                                                                       

  Schupf          2008   4.6 Y               1,125 control   A*β*40, A*β*42 Protofibrillar A*β*42   104 cases developed AD (9.2%)\                                                                                     PNAS
                                                                                                    High A*β*42 level increased threefold risk for onset of AD\                                                        
                                                                                                    Once developing AD, plasma A*β*42, A*β*42/A*β*40 ratio and protofibrillar A*β*42 were significantly decreased      

                                                                                                                                                                                                                       

  Xu              2008   ---                 113 AD\         Autoantibody A*β*40, A*β*42            Anti-A*β*42 dimer antibody was absent in AD\                                                                       Brain Res
                                             205 control                                            A*β*40/42 ratio increase with progression of AD                                                                    

                                                                                                                                                                                                                       

  Lambert         2009   4 Y                 233 dementia\   A*β*40, A*β*42                         prospective 3 city study\                                                                                          Neurol
                                             958 control\                                           A*β*42/A*β*40 ratio showed short-term risk of dementia                                                             
                                             8,414 source                                                                                                                                                              

                                                                                                                                                                                                                       

  Okereke         2009   10 Y prospective    481 Nurses      A*β*40, A*β*42                         Presenile (mean 64 Y) high A*β*42/ A*β*40 ratio correlated with cognitive function 10 years later                  Arch Neurol
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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